Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $9.53M rose 28.4% year over year, behind the +96.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at +75.1% a year.

Context

  • Cost of revenue amounted to 46.5% of revenue in FY2025, up 6.6 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +28.4% toward the trailing-twelve-month pace of +96.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.53M+16.5% QoQ
Last fiscal yearDec 2025
$37.21M+138.5% YoY
LTMMar 2026
$39.32M+96.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.4%——
1 year+138.5%——
3-year CAGR+75.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
37.21M USD
Year-over-year change
+138.5%
4-year CAGR
+94.1%

Cost of Revenue vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 cost of revenue of $39.32M is the 3rd highest of the 10 companies compared; the peer median is $17.04M.
  • Its year-over-year change of +96.0% is the 3rd highest of 8, against a peer median of +32.9%.
  • Cost of revenue amounts to 45.2% of revenue for ETON, versus a peer median of 7.8%.
ETON Competitors Peer median
Cost of Revenue for ETON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$109.99M +25.2%+56.7%16.4%
PHARPharming Group N.V.LTM Mar 2026$46.97M +32.9%+37.5%12.7%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$39.32M +96.0%+75.1%45.2%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$31.49M +204.6%+32.7%4.8%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$17.72M +106.3%+320.3%14.5%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M +44.2%+4.3%1.8%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$3.96M +31.7%+252.4%7.8%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$646K -97.5%-82.7%0.9%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding ETON) $17.04M+32.9%+37.5%7.8%

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.83M21.25M31.64M39.01M79.95M
Cost of Revenue2.62M6.93M10.58M15.6M37.21M
Gross Profit19.21M14.32M21.06M23.41M42.74M
Gross Margin88.0%67.4%66.6%60.0%53.5%
Research & Development6.24M4M3.32M3.26M7.77M
Selling, General & Admin14.47M18.58M18.93M22.75M35.82M
Operating Expenses20.7M22.58M22.25M26.01M42.67M
Depreciation & Amortization462K1.77M901K1.15M4.04M
EBITDA(1.49M)(7.25M)212K(657K)4.27M
EBITDA Margin-6.8%-34.1%0.7%-1.7%5.3%
Operating Income(1.5M)(8.26M)(1.19M)(2.6M)72K
Operating Margin-6.8%-38.9%-3.8%-6.7%0.1%
Interest Income00000
Interest Expense1.04M955K1.06M2.01M4.78M
Other Income / Expenses(460K)(761K)503K(1.21M)(4.63M)
Income Before Tax(1.96M)(9.02M)(689K)(3.81M)(4.56M)
Pre-Tax Margin-9.0%-42.4%-2.2%-9.8%-5.7%
Income Tax Expense00247K15K43K
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (Basic)(0.08)(0.36)(0.04)(0.15)(0.17)
EPS (Diluted)(0.08)(0.36)(0.04)(0.15)(0.17)
Weighted Avg Shares25.21M25.15M25.65M25.9M26.91M
Weighted Avg Shares (Diluted)25.21M25.15M25.65M25.9M26.91M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.